|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Overall, the tumor volume and the PCNA LI% within live tumor areas were reduced by 83% and 99%, respectively, in all TAM-treated groups when compared to the untreated control group.
|
23634930 |
2013 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
To examine cdk activity required for doxorubicin-induced apoptosis, we transfected p21-deficient human tumor DLD1(p21-/-) cells with plasmids carrying wild-type p21 and mutated p21 unable to bind to cdks or proliferating cell nuclear antigen.
|
11020241 |
2000 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Tumors with a PCNA index < 6.056% showed a diameter less than the mean tumoral diameter and a benign clinical course.
|
7745970 |
1995 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Effect of cyclin [corrected] D1 (CCND1) gene polymorphism on tumor formation and behavior in patients with prolactinoma.
|
22967707 |
2012 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
There was a weak correlation between the Ki67 and the PCNA indices (r = 0.38 p < 0.005), but no correlation was found between either index and oestrogen receptor status, patient age or tumour size.
|
7903289 |
1993 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The percentage of hyperdiploid cells for chromosome 17 correlated with p53 overexpression (P< 0.002), PCNA-LI (P< 0.002), increasing tumor grade (P< 0.002) and advanced pathologic stage (P< 0.002).
|
9712438 |
1998 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The authors investigated the prognostic role of p53, c-erbB2, proliferating cell nuclear antigen (PCNA), and DNA flow cytometry in a pathobiological evaluation of a cohort of 30 patients with these neoplasms.
|
8666365 |
1996 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MicroRNA-204 inhibits the proliferation, migration and invasion of human lung cancer cells by targeting PCNA-1 and inhibits tumor growth in vivo.
|
30628638 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These data show no significant correlation coefficient between Ki-67 or PCNA TPIs and SPFs derived from FCM analysis; however, the DNA diploid tumor subset categorized as having a greater than median SPF value had a significantly higher mean Ki-67 but not PCNA proliferation index.
|
8104388 |
1993 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In xenografts, p-NO-ASA inhibited tumor growth by inhibiting proliferation (PCNA and tumor volume), inducing apoptosis (TUNEL positive cells) and reducing NF-κB expression.
|
26184135 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results indicate that RXL motif-based inhibitors will provide selective antiproliferative agents with in vivo efficacy in tumors with deregulated Rb/cyclin D pathways.
|
12615717 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cyclin E protein accumulation was found in 48 different tumour types.
|
12845634 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Increasing evidence demonstrated that cyclin‑dependent kinase regulatory subunit 1B (CKS1B) may be involved in the pathogenesis of various tumor types, including multiple myeloma and breast cancer.
|
31115482 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A. camphorata treatment also inhibited proliferation (cyclin D1 and PCNA) and induced apoptosis (Bcl-2 and TUNEL) when the tumor tissue sections were examined histologically and immunohistochemically.
|
18550246 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A significant difference was found between the PCNA index in p53 positive and p53 negative tumors while the mean PCNA index for the tumors with p53 mutations was not significantly different from the tumors without mutations.
|
9568083 |
1998 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Knowledge of the percentage of PCNA-positive cells could be especially helpful in deciding whether to treat patients with localized disease further because adjuvant chemotherapy affects mainly dividing cells and should, therefore, be more successful in tumors with high proliferative activity.
|
8095852 |
1993 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Herein, we report that metformin significantly inhibited human epidermoid A431 tumor xenograft growth in nu/nu mice, which was associated with a significant reduction in proliferative biomarkers PCNA and cyclins D1/B1.
|
22540890 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
KLF4 and PCNA identify stages of tumor initiation in a conditional model of cutaneous squamous epithelial neoplasia.
|
16357510 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Dysregulation of one of the three D-cyclin genes has been observed in virtually all multiple myeloma tumors.
|
26341922 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumors with higher PCNA index (> or = 31.5%) and negative p53 protein expression appeared to respond better than other tumors, but the difference was not statistically significant.
|
9159335 |
1997 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The expression of cancer-related genes β-catenin, CD44, MMP-2, ICAM-1, and PCNA in the tumor was analyzed by RT-PCR, western blotting and immunohistochemistry in both sublines.
|
29848673 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
As<sub>2</sub>O<sub>3</sub>-NPs inhibited tumor growth more strongly than As<sub>2</sub>O<sub>3</sub> or control, a finding likely attributed to the downregulation of PCNA and DNMT-related proteins and the upregulation of GSDME-N.
|
31637008 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Low levels of amplified C-myc and cyclin-D cells seem to be the reason for this tumor to be benign, while RARa could not be effective without the association of some other gene such as PML.
|
22593003 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Various methods of measuring tumor cell proliferation (proliferating cell nuclear antigen, bromodeoxyuridine, Ki-67, nucleolar organizer regions, and DNA flow cytometry) are being compared with each other and correlated with clinical outcome in an attempt to validate these methods and to discover the most relevant one.
|
8494905 |
1993 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Results of quantitative DNA measurements and PCNA scores were compared to clinical symptoms, histology, and time between first onset of symptoms and diagnosis of the tumor.
|
7904813 |
1994 |